Ep4 inhibitors and use thereof
AssigneesArrys Therapeutics, Inc., AskAt Inc.
InventorsMark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
Life of this patent
Estimating the term…
Abstract
The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
Claims24
A method for treating a cancer in a patient comprising administering to the patient an agent that inhibits prostaglandin EP4 receptor (EP4) activity in combination an immuno-oncology agent, wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, gastric cancer, multiple myeloma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), pancreatic cancer, liver cancer, hepatocellular cancer, neuroblastoma, other solid tumors or other hematological cancers.
(canceled)
4-9. (canceled)
11-15. (canceled)
17-26. (canceled)
28-37. (canceled)
51-54. (canceled)
Dependencies are inferred from the claim text.